<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136068</url>
  </required_header>
  <id_info>
    <org_study_id>Digoxin RCT</org_study_id>
    <nct_id>NCT03136068</nct_id>
  </id_info>
  <brief_title>Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation</brief_title>
  <official_title>Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation: a Placebo-controlled, Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FPA Womenâ€™s Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to measure the effect of digoxin injection on Dilation and
      Evacuation (D&amp;E) procedure duration. Digoxin is the most commonly used feticidal agent among
      family planning subspecialists, and is commonly used for a variety of reasons including
      provider preference, patient preference, and concerns over legal status of later D&amp;E
      procedures. There have been several studies on digoxin administration, adverse effects, and
      impact on the D&amp;E procedure, but doctors want to clarify how digoxin effects D&amp;E procedure
      time, if at all.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>Beginning to end of procedure (between 5 minutes and 1 hour)</time_frame>
    <description>First instrument into uterus until last instrument out of uterus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total procedure duration</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Achievement of fetal demise in patients receiving digoxin</measure>
    <time_frame>Day 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measured blood loss</measure>
    <time_frame>Day 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Complications</measure>
    <time_frame>Day 2</time_frame>
    <description>hemorrhage, perforation, cervical laceration requiring suture repair, out-of-hospital delivery, infection, inability to complete injection, other complications of the injection itself, and patient symptoms such as nausea and vomiting</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Abortion</condition>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Trans-abdominal injection</description>
    <arm_group_label>Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Trans-abdominal injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 weeks 0 days-24 weeks 0 days gestation

          -  English or Spanish speaking

          -  18 years or older

        Exclusion Criteria:

          -  Under 18

          -  Contraindications to digoxin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer L Kerns, MD, MPH</last_name>
    <phone>510-502-4340</phone>
    <email>Jennifer.Kerns@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geffan A Pearlson</last_name>
    <phone>541-731-9567</phone>
    <email>Geffan.Pearlson@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FPA Women's Health</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Steward, MD, MSc, FACOG</last_name>
      <phone>646-417-1685</phone>
      <email>rsteward@allcare-med.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SFGH Women's Options Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Drey, MD</last_name>
      <phone>415-206-3659</phone>
      <email>edrey@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lovejoy Surgicenter</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Bednareck, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jennifer Kerns, MD, MS, MPH</investigator_full_name>
    <investigator_title>Assistant Professor department of Obstetrics, Gynecology and Reproductive Sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

